OYST

NASDAQ

Oyster Point Pharma Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2019

News25/Ratings3

Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company's lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that has completed Phase III clinical trial for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratopathy. Oyster Point Pharma, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey.

Latest news

25 items

792dNEWS
Health Care Becomes Most Overweighted Sector As Hedge Funds Crowd Into Magnificent 7
Six out of the 10 largest holdings in over 700 aggregated hedge fund portfolios are increasingly concentrated towards the ‘Magnificent Seven' stocks, with Tesla being the sole exception, according to the latest report by Goldman Sachs. What Happened: Insights from Goldman Sachs’ Hedge Fund Trend Monitor, an analysis led by Ben Snider, show an overzealous preference for just several mega-caps. This enthusiasm does not mirror their market weight. The Magnificent Seven accounts for a record 13% of the aggregate hedge fund long portfolios. Yet, it remains significantly underweighted compared to a 26% collective stake in the Russell 3000 — underscoring a cautious approach towards mega-cap
1164d13D/G
SEC Form SC 13G/A filed by Oyster Point Pharma Inc. (Amendment)
SC 13G/A - Oyster Point Pharma, Inc. (0001720725) (Subject)
1164d13D/G
SEC Form SC 13G/A filed by Oyster Point Pharma Inc. (Amendment)
SC 13G/A - Oyster Point Pharma, Inc. (0001720725) (Subject)
1196dSEC
SEC Form 15-12G filed by Oyster Point Pharma Inc.
15-12G - Oyster Point Pharma, Inc. (0001720725) (Filer)
1196dSEC
Oyster Point Pharma Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits (Amendment)
8-K/A - Oyster Point Pharma, Inc. (0001720725) (Filer)
1196d13D/G
SEC Form SC 13D/A filed by Oyster Point Pharma Inc. (Amendment)
SC 13D/A - Oyster Point Pharma, Inc. (0001720725) (Subject)
1200d13D/G
SEC Form SC 13D/A filed by Oyster Point Pharma Inc. (Amendment)
SC 13D/A - Oyster Point Pharma, Inc. (0001720725) (Subject)
1204dSEC
SEC Form EFFECT filed by Oyster Point Pharma Inc.
EFFECT - Oyster Point Pharma, Inc. (0001720725) (Filer)
1204d13D/G
SEC Form SC 13D/A filed by Oyster Point Pharma Inc. (Amendment)
SC 13D/A - Oyster Point Pharma, Inc. (0001720725) (Subject)
1204dINSIDER
SEC Form 4 filed by Invopps Gp Iv, L.L.C.
4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
1205dINSIDER
SEC Form 4 filed by Versant Venture Capital Vi, L.P.
4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
1205dINSIDER
SEC Form 4: Behbahani Ali returned 13,639 shares to the company, closing all direct ownership in the company (for tax liability)
4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
1205dINSIDER
SEC Form 4 filed by New Enterprise Associates 14, L.P.
4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
1205dINSIDER
SEC Form 4: Weisner Aimee S returned 36,764 shares to the company, closing all direct ownership in the company (for tax liability)
4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
1205dINSIDER
SEC Form 4: Tsai Benjamin returned 3,573 shares to the company, closing all direct ownership in the company (withholding obligation)
4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
1205dINSIDER
SEC Form 4: Santel Donald J returned 8,198 shares to the company, closing all direct ownership in the company to cover withholding tax
4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
1205dINSIDER
SEC Form 4: Ozawa Clare returned 14,637 shares to the company, closing all direct ownership in the company (withholding tax)
4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
1205dINSIDER
SEC Form 4: Nau Jeffrey covered exercise/tax liability with 2,607 shares and returned 48,975 shares to the company, closing all direct ownership in the company to satisfy withholding tax
4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
1205dINSIDER
SEC Form 4: Murray Mark Anthony returned 122,086 shares to the company, closing all direct ownership in the company to satisfy withholding tax
4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
1205dINSIDER
SEC Form 4: Lochner Daniel covered exercise/tax liability with 938 shares and returned 20,236 shares to the company, closing all direct ownership in the company (tax liability)
4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
1205dINSIDER
SEC Form 4: Eliades George Christopher returned 28,624 shares to the company, closing all direct ownership in the company (tax liability)
4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
1205dINSIDER
SEC Form 4: Atieh Michael G returned 8,671 shares to the company, closing all direct ownership in the company (withholding obligation)
4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
1206dSEC
SEC Form 25-NSE filed by Oyster Point Pharma Inc.
25-NSE - Oyster Point Pharma, Inc. (0001720725) (Subject)
1206dSEC
SEC Form S-8 POS filed by Oyster Point Pharma Inc.
S-8 POS - Oyster Point Pharma, Inc. (0001720725) (Filer)
1206dSEC
SEC Form S-8 POS filed by Oyster Point Pharma Inc.
S-8 POS - Oyster Point Pharma, Inc. (0001720725) (Filer)